Crackdown on Deceptive Weight Loss Drug Ads Marks Victory for Consumers
Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829
Washington, DC – Justice delayed was justice denied to millions of Americans who have been exposed to a flood of deceptive advertising about the safety of the same weight loss drugs that the Food and Drug Administration warns are not approved and “could be risky for patients.” Now, FDA is standing up for consumers by sending 100 cease-and-desist letters that tell online sellers of compounded GLP-1 drugs that it is a breach of FDA regulation to tout the benefits of the weight-loss drugs without any mention of side effects and to stop this “false or misleading” marketing.
“Americans need a cop on the beat to protect them from the rampant disinformation now circulating online that causes consumers to tune out the advice of the FDA and leading medical societies and opt for drugs that may cause harm or could be fakes, says Nancy Glick, Director of Food and Nutrition Policy. The National Consumers League welcomes FDA’s commitment to monitor the content and claims of companies promoting GLP-1 weight loss medicines and other prescription drugs and to enforce prescription drug advertising regulations aggressively.
###
About the National Consumers League (NCL)
The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.
